DIA 2020 Virtual Global Annual Meeting

Component Type: Forum
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-20-722-L04-P; CME 1.00; IACET 1.00; RN 1.00

Patient engagement is an essential component of the drug development process. Involving the patient community early on can accelerate and enhance research efforts. The process of securing input from the patient community in research is often conducted as a bidirectional process between industry sponsors and a community of people living with a common illness/disease experience. This process can be enhanced by including stakeholders with unique expertise in patient engagement and communication. These stakeholders enhance credibility and relationship building between industry and patient communities, which increases the success and quality of patient engagement, and optimizes the process of learning from patient communities. Patient advocacy organizations, patient engagement experts within a biopharmaceutical company and consulting organizations are all stakeholders that have unique expertise. In this session, examples of successful partnership with the patient community facilitated by each of these stakeholders will be discussed.

Learning Objectives

Recognize the different models of patient engagement and benefits of leveraging each to ensure early involvement of the patient community in drug development; Describe methods to encourage collaboration in therapeutic areas with multiple patient stakeholders to create and leverage a unified community voice; Identify best practices for capturing and interpreting meaningful input from special patient populations, such as people with cognitive impairment.

Chair

Karlin Schroeder, MA

Speaker

Panelist
Patricia Davies

Panelist
Fernanda D. Copeland, MS

Panelist
Madeline Corrigan, PhD